MainNumber of industry meetings held, including face-to-face meetings and meetings held over the telephone, within the month that OBP participated in. These meeting facilitate communication with industry to help ensure appropriate product development. <br>These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research. </b> NumberMeasure was implemented starting March 2010

Oct 2009N/ANov 2009N/ADec 2009N/AJan 2010N/AFeb 2010N/AMar 201030Apr 201022May 201017Jun 201023Jul 201016Aug 201020Sep 201028

FY 2011 Total: 329

Oct 201023Nov 201025Dec 201023Jan 201123Feb 201127Mar 201133Apr 201135May 201127Jun 201136Jul 201126Aug 201134Sep 201117

FY 2012 YTD: 86

Oct 201130Nov 201130Dec 201126Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012http://www.fda.gov/AboutFDA/Transparency/track/ucm206444.htmFDA-TRACK CDER DashboardMainNumber of OBP-managed product quality meetings, including teleconferences and in-person meetings, held with industry within the month. These meeting facilitate communication with industry to help ensure appropriate product development. However they are focused on product quality, manufacturing and related safety issues.Number

Oct 20095Nov 20093Dec 20093Jan 20107Feb 20104Mar 20104Apr 20109May 20104Jun 20104Jul 20103Aug 20101Sep 20104

FY 2011 Total: 59

Oct 20104Nov 20105Dec 20107Jan 20114Feb 20113Mar 20118Apr 20111May 20113Jun 20115Jul 20116Aug 20115Sep 20118

FY 2012 YTD: 15

Oct 20117Nov 20114Dec 20114Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012